Clearmind Medicine Inc. Files Annual Report on Form 20-F for the Fiscal Year Ended October 31, 2025

Clearmind Medicine (Nasdaq: CMND) announced it filed its Annual Report on Form 20-F for the fiscal year ended October 31, 2025 with the U.S. Securities and Exchange Commission on January 20, 2026.

Rhea-AI Summary

Clearmind Medicine (Nasdaq: CMND) announced it filed its Annual Report on Form 20-F for the fiscal year ended October 31, 2025 with the U.S. Securities and Exchange Commission on January 20, 2026. The report is available on the SEC website and on Clearmind's Investor Relations website. Shareholders may request free copies by contacting Clearmind's Investor Relations Department via the provided email address. The filing relates to the company's clinical-stage work on neuroplastogen-derived therapeutics.

Argus Jan 21 session

-3.03% close to close Open Argus

Details

News Market Reaction – CMND

On Jan 21, the first trading day after this news, CMND closed 3.03% below the previous close.

Data tracked by StockTitan Argus for the Jan 21 session.

Key Figures

Operating loss 2025: $5,667,177 Operating loss 2024: $5,744,925 Operating loss 2023: $6,303,434 +5 more

Operating loss 2025

$5,667,177

Year ended Oct 31, 2025 (Form 20-F)

Operating loss 2024

$5,744,925

Year ended Oct 31, 2024 (Form 20-F)

Operating loss 2023

$6,303,434

Year ended Oct 31, 2023 (Form 20-F)

Net loss 2025

$3,856,983

Year ended Oct 31, 2025 (Form 20-F)

Accumulated deficit

$27,879,724

As of Oct 31, 2025 (Form 20-F)

Negative operating cash flow

$4,734,498

Year ended Oct 31, 2025 (Form 20-F)

Cash & equivalents

$3,923,058

As of Oct 31, 2025 (Form 20-F)

Registered direct gross proceeds

$1,297,012.76

Nov 26, 2025 prospectus supplement

Historical Context

5 past events · Latest: Jan 14

5 events

1. Jan 14

   Clinical trial update

   24h Move

   +0.4%

   Completion of treatment in all patients of second CMND-100 cohort.

2. Dec 31

   Listing compliance

   24h Move

   -2.7%

   Regained compliance with Nasdaq minimum bid price requirement.

3. Dec 24

   Year-in-review update

   24h Move

   -5.8%

   Summary of 2025 clinical advances and expanded global footprint.

4. Dec 16

   Clinical trial update

   24h Move

   -3.7%

   Completion of enrollment for second cohort in CMND-100 trial.

5. Dec 12

   Scientific review highlight

   24h Move

   +3.6%

   Peer-reviewed review spotlighting MEAI’s potential in AUD treatment.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

form 20-f, form 6-k, form f-3, form s-8, +3 more

7 terms

form 20-f regulatory

"filed its Annual Report on Form 20-F for the fiscal year"

Form 20-F is the standardized annual disclosure that non-U.S. companies must file with the U.S. securities regulator when their shares are traded in the U.S.; it contains audited financial statements, a plain-language description of the business, management discussion, governance details and key risk factors. It matters to investors because it provides a consistent, comparable company “report card” and rulebook, helping buyers assess financial health, governance and risks before investing.

form 6-k regulatory

"filed a Form 6-K to furnish a press release announcing"

A Form 6-K is a report that companies listed in certain countries file to provide important updates, such as financial results, corporate changes, or other significant information, to regulators and investors. It functions like an official company update or news release, helping investors stay informed about developments that could affect their investment decisions.

form f-3 regulatory

"incorporated by reference into Clearmind’s existing registration statements on Forms F-3"

Form F-3 is a U.S. securities filing that lets eligible foreign companies pre-register and then quickly sell shares or other securities to raise money, because they already meet ongoing reporting and size tests. For investors it signals that the company is up-to-date with regulatory disclosure and has an efficient way to issue new securities — similar to a pre-approved credit line — which can mean faster capital raises but also potential dilution of existing holdings.

form s-8 regulatory

"and Form S-8 (File No. 333-283695)."

A Form S-8 is a U.S. Securities and Exchange Commission registration that lets a public company set aside shares for employee benefit plans and stock-based compensation. Think of it as opening a dedicated account that authorizes the company to issue or reserve stock for workers and directors; it matters to investors because it enables share dilution when those awards are granted or exercised and signals how management is compensated and incentivized.

f-1/a regulatory

"[F-1/A] Clearmind Medicine Inc. Amended Foreign Issuer IPO Registration"

An F-1/A is an amended registration document filed with U.S. regulators by a non‑U.S. company that plans to sell securities in the U.S.; it updates or corrects the original F-1 filing with new information such as revised financials, risk factors, or terms of the offering. Investors pay attention because amendments can change the investment’s risks or timing—think of it like a revised brochure for a product launch that may alter your decision to buy or wait.

pre-funded warrants financial

"pre-funded warrants to purchase up to 2,865,960 common shares."

Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.

registered direct offering financial

"entered into a definitive securities purchase agreement for a registered direct offering"

A registered direct offering is a way for a company to sell new shares of its stock directly to select investors with regulatory approval. This method allows the company to raise funds quickly and efficiently without needing a public auction, similar to offering exclusive access to a limited number of buyers. For investors, it often provides an opportunity to purchase shares at a favorable price, while giving the company immediate access to capital.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Vancouver, Canada, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced that it has filed its Annual Report on Form 20-F for the fiscal year ended October 31, 2025, with the U.S. Securities and Exchange Commission (the 'SEC').

The report is available on the SEC's website, at www.sec.gov and Clearmind’s Investor Relations website, at https://www.clearmindmedicine.com/investors.

Shareholders can obtain copies of Galmed's Annual Report on Form 20-F, free of charge, by making a request within a reasonable period of time to Clearmind’s Investor Relations Department at invest@clearmindmedicine.com.

About Clearmind Medicine Inc.

Clearmind is a clinical-stage psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods, or supplements.

The Company’s intellectual portfolio currently consists of nineteen patent families, including 31 granted patents. The Company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.

Shares of Clearmind are listed for trading on Nasdaq under the symbol "CMND" and the Frankfurt Stock Exchange under the symbol “CWY0.”

For further information, visit: https://www.clearmindmedicine.com or contact:

Investor Relations
invest@clearmindmedicine.com

Telephone: (604) 260-1566
US: CMND@crescendo-ir.com

General Inquiries
Info@Clearmindmedicine.com
www.Clearmindmedicine.com

Forward-Looking Statements:

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s annual report on Form 20-F for the fiscal year ended October 31, 2025 and subsequent filings with the SEC. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Clearmind is not responsible for the contents of third-party websites.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Clearmind (CMND) file on January 20, 2026?

Clearmind filed its Annual Report on Form 20-F for the fiscal year ended October 31, 2025.

Where can I access Clearmind's Form 20-F for fiscal year ended October 31, 2025 (CMND)?

The report is available on the SEC website (www.sec.gov) and on Clearmind's Investor Relations website.

How can shareholders obtain a free copy of Clearmind's Form 20-F (CMND)?

Shareholders can request a free copy by contacting Clearmind's Investor Relations Department at invest@clearmindmedicine.com.

What fiscal period does Clearmind's filed 20-F cover for CMND?

The filing covers the fiscal year ended October 31, 2025.

Does the Form 20-F filing mention Clearmind's clinical focus (CMND)?

Yes. The company is described as a clinical-stage biotech focused on neuroplastogen-derived therapeutics.